Danaher Co. (NYSE:DHR) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Danaher Co. (NYSE:DHR) by 0.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 763,400 shares of the conglomerate’s stock after purchasing an additional 3,607 shares during the period. Natixis Advisors LLC owned approximately 0.11% of Danaher worth $190,735,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new stake in shares of Danaher during the 4th quarter worth approximately $306,000. Gilbert & Cook Inc. boosted its stake in shares of Danaher by 4.9% during the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after acquiring an additional 86 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Danaher by 4.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 149,379 shares of the conglomerate’s stock worth $34,557,000 after acquiring an additional 6,158 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in Danaher by 1.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares in the last quarter. Finally, Accretive Wealth Partners LLC lifted its stake in Danaher by 12.9% in the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after buying an additional 414 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR traded up $2.29 during mid-day trading on Friday, reaching $269.31. 4,600,180 shares of the company traded hands, compared to its average volume of 1,915,256. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market cap of $194.50 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The stock has a fifty day simple moving average of $260.05 and a 200-day simple moving average of $255.19.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period last year, the firm posted $2.05 earnings per share. Equities research analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Analyst Ratings Changes

DHR has been the topic of a number of recent research reports. Evercore ISI reduced their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Barclays upped their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Leerink Partners upped their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target for the company. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.